 Soleno Therapeutics is currently developing Diazoxide Choline Controlled-Release tablets and has a distinctive advantage in how well-documented the safety profile of DCCRs parent molecule, Diazoxide, is. Subsequent interim results from SLNOs open-label study published in December 2020 are more encouraging, indicating highly significant reduction in hyperphagia levels and PWS-related behaviour patterns. 